QLOSI (pilocarpine hydrochloride)
QLOSI is a medication that treats presbyopia in adult patients. It helps patients with this condition by improving their near visual acuity, making it easier to focus on close objects. This treatment is used to enhance a patient's depth of focus while still allowing the eye to respond naturally to light.
How QLOSI Works
This drug works by activating specific receptors on the smooth muscles of the eye, including the iris sphincter and ciliary muscle. This action causes the pupil to constrict, which increases the eye's depth of focus and improves near vision.
Details
- Status
- Prescription
- First Approved
- 2023-10-17
- Patent Cliff
- 2037
- Routes
- OPHTHALMIC
- Dosage Forms
- SOLUTION/DROPS
QLOSI Approval History
What QLOSI Treats
1 indicationsQLOSI is approved for 1 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Presbyopia
QLOSI Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to QLOSI
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
QLOSI FDA Label Details
Indications & Usage
FDA Label (PDF)QLOSI is indicated for the treatment of Presbyopia.
QLOSI Patents & Exclusivity
Patents (4 active)
Exclusivity
Pro Intelligence Preview
Deep insights for QLOSI
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2037
- • 4 active patents
Trial Analysis
- • Clinical trial tracking
- • Development stage analysis
Competitive Landscape
- • 3 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.